Recommendation: Genotype should be mandatory before adjuvant imatinib administration [III, B], since mutations involving 557/558 of exon 11 in KIT gene determine a relapse-free-survival risk similar to high risk in patients with gastric and intermediate-risk GIST [12]. Here, KIT is linked to gastrointestinal stromal tumor.